Education
About Us
Working with TipRanks
Follow Us
Modalis Therapeutics Corporation (JP:4883)
:4883
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥52.00 - ¥119.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥4.90B
Enterprise Value¥1.73B
Total Cash (Recent Filing)¥3.26B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.21
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.95
Shares Outstanding87,484,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet LeverageReported zero total debt in 2024–2025 provides a durable financial cushion versus leveraged peers. Low leverage reduces fixed interest burdens, preserves optionality for R&D financing, and lowers near-term default risk, supporting runway while programs mature.
Platform-focused R&D Targeting Regulatory RegionsA platform approach that targets regulatory genomic regions is a structural advantage: it enables repeatable discovery across indications, can generate multiple program candidates, and concentrates expertise and IP in a specialized scientific niche.
Focus On Genetically Driven Conditions / Unmet NeedTargeting genetically driven diseases with high unmet need aligns the company with durable structural demand, potential premium clinical value, and partner interest. This focus can sustain long-term relevance even if clinical timelines are extended.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicates ongoing funding dependence. Over the coming months this elevates liquidity and dilution risk, constrains discretionary R&D investment pacing, and reduces resilience to capital-market stress.
Minimal-to-zero RevenueNearly absent revenue means the business lacks validated commercial cash generation. Long-term viability hinges on preclinical/clinical success or licensing partnerships, increasing execution risk and prolonging reliance on external capital.
Eroding Shareholders' EquityMaterial declines in shareholders’ equity from repeated losses shrink the balance-sheet buffer. That reduction limits future borrowing capacity, heightens dilution probability if equity raises are needed, and weakens financial flexibility over months ahead.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥52.00 and its highest was ¥119.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥4.90B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is May 13, 2026 which is in 66 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on Feb 12, 2026. The company reported -¥3.95 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.95.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 87,484,100 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥3.95 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.724%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―